Display options
Cite
Doekhie FS, Morreau H, de Bock GH, et al. Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence. Cancer Microenviron. 2008;1(1):141-51doi: 10.1007/s12307-008-0014-3.
Doekhie, F. S., Morreau, H., de Bock, G. H., Speetjens, F. M., Dekker-Ensink, N. G., Putter, H., van de Velde, C. J., Tollenaar, R. A., & Kuppen, P. J. (2008). Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence. Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 1(1), 141-51. https://doi.org/10.1007/s12307-008-0014-3
Doekhie, Fania S, et al. "Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence." Cancer microenvironment : official journal of the International Cancer Microenvironment Society vol. 1,1 (2008): 141-51. doi: https://doi.org/10.1007/s12307-008-0014-3
Doekhie FS, Morreau H, de Bock GH, Speetjens FM, Dekker-Ensink NG, Putter H, van de Velde CJ, Tollenaar RA, Kuppen PJ. Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence. Cancer Microenviron. 2008 Dec;1(1):141-51. doi: 10.1007/s12307-008-0014-3. Epub 2008 Aug 06. PMID: 19308692; PMCID: PMC2654349.
Copy Download .nbib Format: NLM
Share it on

Cancer Microenviron. 2008 Dec;1(1):141-51. doi: 10.1007/s12307-008-0014-3. Epub 2008 Aug 06.

Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence.

Cancer microenvironment : official journal of the International Cancer Microenvironment Society

Fania S Doekhie, Hans Morreau, Geertruida H de Bock, Frank M Speetjens, N Geeske Dekker-Ensink, Hein Putter, Cornelis J H van de Velde, Rob A E M Tollenaar, Peter J K Kuppen

Affiliations

  1. Department of Surgery, K6-R, Leiden University Medical Center, Leiden, The Netherlands.

PMID: 19308692 PMCID: PMC2654349 DOI: 10.1007/s12307-008-0014-3

Abstract

Up to 30% of curatively resected colorectal cancer patients with tumor-negative lymph nodes, show disease recurrence. We assessed whether these high-risk patients can be identified by examining primary tumors for the following blood and lymphatic vasculature markers: A) sialyl Lewis X (sLeX), vascular endothelial growth factor (VEGF)-C and VEGF-D expression; B) blood and lymphatic microvessel density (BMVD/LMVD); and C) the presence of blood and lymphatic vessel invasion. Thirty-six cases (disease recurrence within 5 years) and 72 controls (no disease recurrence for at least 5 years) were selected in a case-control design. Tumor sections were stained by antibodies CSLEX1 (sLeX), anti-VEGF-C, anti-VEGF-D, anti-CD31 (BMVD) or D2-40 (LMVD) to determine the parameters as mentioned above. A multivariate analysis showed sLeX expression and high LMVD (odds ratio 5.1, 95% confidence interval 1.3-20.0 and odds ratio 3.1, 95% confidence interval 1.0-10.0, respectively) to be independent factors predicting disease recurrence. Expression of sLeX correlated with liver metastases (P = 0.015). A high LMVD was related to regional intra-abdominal or intrapelvic metastases in lymph nodes and distant metastases other than in the liver and lungs such as peritoneum, bones, brain and adrenal glands (P = 0.004). A high BMVD in the invasive front correlated with lung metastases (P = 0.018). We show that high-risk node-negative colorectal cancer patients can be identified by primary tumor assessment for sLeX expression and LMVD. Our results are consistent with the notion that both lymphatic and hematogenous metastasis play a role in colorectal cancer.

References

  1. Hum Pathol. 2006 Sep;37(9):1193-9 - PubMed
  2. J Surg Oncol. 2000 Oct;75(2):98-102 - PubMed
  3. Nature. 2007 Jan 4;445(7123):111-5 - PubMed
  4. Cancer Res. 1991 Sep 15;51(18 Suppl):5054s-5059s - PubMed
  5. APMIS. 1988 May;96(5):379-94 - PubMed
  6. Br J Cancer. 2006 Jun 19;94(12):1823-32 - PubMed
  7. Int J Colorectal Dis. 2007 Jan;22(1):39-48 - PubMed
  8. Lancet. 2007 Dec 15;370(9604):2020-9 - PubMed
  9. J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 - PubMed
  10. Int J Biochem Cell Biol. 2001 Apr;33(4):421-6 - PubMed
  11. Cancer Res. 2000 Jan 15;60(2):203-12 - PubMed
  12. Curr Opin Urol. 2006 Sep;16(5):367-71 - PubMed
  13. Science. 1990 Nov 23;250(4984):1130-2 - PubMed
  14. World J Surg. 2002 Mar;26(3):384-9 - PubMed
  15. J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 - PubMed
  16. N Engl J Med. 1991 Jan 3;324(1):1-8 - PubMed
  17. Cancer Chemother Pharmacol. 1999;43 Suppl:S3-10 - PubMed
  18. Cancer Res. 1993 Aug 1;53(15):3632-7 - PubMed
  19. Mod Pathol. 2006 Oct;19(10):1317-23 - PubMed
  20. Nat Med. 2001 Feb;7(2):186-91 - PubMed
  21. Surg Endosc. 2007 Dec;21(12):2142-6 - PubMed
  22. Clin Cancer Res. 2005 Nov 1;11(21):7637-42 - PubMed
  23. Histopathology. 2005 Apr;46(4):396-402 - PubMed
  24. J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 - PubMed
  25. Cancer Metastasis Rev. 1989 Aug;8(2):98-101 - PubMed
  26. J Am Coll Surg. 1994 Jul;179(1):11-7 - PubMed
  27. Br J Cancer. 2000 Oct;83(7):887-91 - PubMed
  28. Int J Cancer. 2000 Oct 15;88(2):281-6 - PubMed
  29. J Exp Clin Cancer Res. 2002 Mar;21(1):107-13 - PubMed
  30. Science. 1990 Nov 23;250(4984):1132-5 - PubMed
  31. Dis Colon Rectum. 2007 Mar;50(3):308-14 - PubMed
  32. N Engl J Med. 1990 Feb 8;322(6):352-8 - PubMed
  33. Histopathology. 2006 Nov;49(5):493-7 - PubMed
  34. J Clin Oncol. 1999 May;17(5):1356-63 - PubMed
  35. Adv Anat Pathol. 2006 Nov;13(6):308-15 - PubMed
  36. Clin Exp Metastasis. 2008;25(4):335-44 - PubMed
  37. Microsc Res Tech. 2003 Feb 1;60(2):171-80 - PubMed
  38. Lancet. 1987 Jun 6;1(8545):1303-6 - PubMed

Publication Types